Zymeworks Inc. - Common Stock (ZYME)
Frequently Asked Questions About Zymeworks Inc. - Common Stock (ZYME)
Does Zymeworks Inc. have any partnerships?
Yes, Zymeworks Inc. has established several strategic partnerships and collaborations with leading pharmaceutical companies and research institutions. These partnerships enhance its capabilities in clinical development and expand its reach in drug discovery and commercialization.
How does Zymeworks benefit from its research collaborations?
Research collaborations allow Zymeworks to leverage external expertise and technologies, thereby enhancing its own research capabilities. These collaborations also help the company to share risks associated with drug development and accelerate the path to market for new therapies.
How does Zymeworks ensure the safety of its product candidates?
Zymeworks Inc. conducts rigorous preclinical and clinical trials to evaluate the safety and efficacy of its product candidates. The company adheres to strict regulatory standards and guidelines set forth by agencies like the FDA to ensure patient safety.
How does Zymeworks keep its investors informed?
Zymeworks maintains transparency with its investors through regular updates via press releases, quarterly earnings reports, and participation in investor conferences. The company prioritizes clear communication about its progress, pipeline developments, and strategic initiatives.
Is Zymeworks Inc. publicly traded?
Yes, Zymeworks Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol 'ZYME'. The company went public in 2018 to raise capital for its research and development efforts.
What are bispecific antibodies?
Bispecific antibodies are engineered antibodies that can simultaneously bind to two distinct antigens or epitopes. This dual targeting ability makes them promising therapeutic candidates for treating complex diseases, particularly in oncology, where they can engage both cancer cells and immune effector cells.
What are the competitive advantages of Zymeworks?
Zymeworks' competitive advantages include its proprietary Azymetric™ technology, a well-integrated research and development team, strategic partnerships, and a robust clinical pipeline. These factors position the company uniquely within the biotechnology space to address complex medical challenges effectively.
What does Zymeworks Inc. do?
Zymeworks Inc. is a biotechnology company focused on developing multifunctional therapeutic proteins. The company's platform leverages its proprietary Azymetric™ technology to create a new class of therapeutics, including antibody-drug conjugates, bispecific antibodies, and other biologics intended to treat various types of cancers and other serious diseases.
What is Azymetric™ technology?
Azymetric™ technology is Zymeworks' proprietary platform for designing and engineering multifunctional proteins. It enables the creation of versatile biologics with enhanced therapeutic potential, such as improved targeting, efficiency, and safety profiles.
What is the company's lead product candidate?
Zymeworks Inc.'s lead product candidate is ZW25, a bispecific antibody designed to target the cancer-associated antigens. It is being investigated in various clinical studies for the treatment of solid tumors.
What is the long-term vision of Zymeworks Inc.?
Zymeworks Inc.'s long-term vision is to become a leading biotechnology company that delivers innovative and transformative therapies for patients with cancer and other serious diseases. The company aims to continuously expand its technological capabilities and therapeutic offerings to improve patient outcomes globally.
What is Zymeworks Inc.'s commitment to sustainability?
Zymeworks Inc. is committed to sustainability and corporate social responsibility. The company focuses on ethical practices in its operations, employee welfare, and environmental stewardship as part of its corporate ethos.
What is Zymeworks Inc.'s pipeline?
Zymeworks Inc. has a diverse pipeline of product candidates in various stages of development. This includes several bispecific antibodies and antibody-drug conjugates aimed at addressing a range of cancers, as well as preclinical candidates that are being investigated for other diseases.
What is Zymeworks' approach to drug development?
Zymeworks adopts a systematic approach to drug development, leveraging its proprietary technologies and robust research capabilities to create and optimize novel therapeutic candidates. The company emphasizes innovation, collaboration, and thorough validation throughout the development process.
What markets does Zymeworks Inc. operate in?
Zymeworks Inc. operates primarily in the biotechnology and pharmaceutical markets. The company focuses on developing innovative therapies for oncology and other serious diseases, addressing unmet medical needs in these areas.
What therapeutic areas does Zymeworks focus on?
Zymeworks primarily focuses on oncology as its therapeutic area. Its research includes the development of therapies for various types of cancer, aiming to provide innovative treatment options for patients with serious unmet medical needs.
When was Zymeworks Inc. founded?
Zymeworks Inc. was founded in 2003. The company was established in Vancouver, Canada, and has since grown to become a leader in the field of protein engineering and therapeutic development.
Where is Zymeworks Inc. headquartered?
Zymeworks Inc. is headquartered in Vancouver, British Columbia, Canada. The company also has offices in Seattle, Washington, which supports its research and development efforts.
Who are the key executives at Zymeworks Inc.?
The executive team at Zymeworks Inc. includes experienced leaders in the biotechnology field. Notable figures include Dr. Kenneth Gordon, the company's CEO, and other executives with extensive backgrounds in drug development, finance, and operations.
What is the current price of Zymeworks Inc. - Common Stock?
The current price of Zymeworks Inc. - Common Stock is 10.72
When was Zymeworks Inc. - Common Stock last traded?
The last trade of Zymeworks Inc. - Common Stock was at 1:21 pm EDT on April 4th, 2025
What is the market capitalization of Zymeworks Inc. - Common Stock?
The market capitalization of Zymeworks Inc. - Common Stock is 619.31M
How many shares of Zymeworks Inc. - Common Stock are outstanding?
Zymeworks Inc. - Common Stock has 57.77M shares outstanding.